Highmark among insurers that won't cover new Alzheimer's treatment for some customers

Some private insurers are balking at paying for the first drug fully approved to slow mental decline in Alzheimer’s patients. Insurers selling coverage in North Carolina, Pennsylvania and New York, among other states, told The Associated Press they won’t cover Leqembi with insurance offered on the individual market and through

Related Keywords

Tufts Medical Center ,Massachusetts ,United States ,West Virginia ,Delaware ,Cheektowaga ,New York ,Pennsylvania ,Boston ,Japan ,Cambridge ,Cambridgeshire ,United Kingdom ,North Carolina ,Japanese ,Heidi Syropoulos ,Bonnie Bortz ,Kaiser Permanente ,Christine Mann ,Jack Hoadley ,James Chambers ,Greg Warren ,Juliette Cubanski ,N Dent Neurologic Institute ,Georgetown University Center On Health Insurance Reforms ,Society Of Actuaries ,Drug Administration ,Biogen Inc ,Associated Press ,Elevance Health ,Massachusetts Based Biogen ,Dent Neurologic Institute ,Blue Cross ,Blue Shield ,Philadelphia Based Independence Blue ,Blue Cross Shield ,Medicare Advantage ,Medical Center ,Georgetown University ,Health Insurance ,